Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BGI GENOMICS CO., LTD. is currently engaged in the patent prosecution process within the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action, which is being reviewed by 1 distinct examiner. This action is located within 1 distinct art unit, indicating a focused effort on a specific genomic or biotechnological innovation. The presence of 1 pending office action suggests a targeted prosecution strategy with limited administrative requirements.
The busiest examiner for the company is YOUNG, BRIAN ELLIS, who is responsible for 1 pending office action. This examiner handles the entirety of the company's current pending workload. Because there is 1 distinct examiner and 1 distinct art unit involved, the prosecution strategy is centralized. Practitioners can focus their efforts on the specific technical requirements of YOUNG, BRIAN ELLIS within the Biotechnology & Pharmaceuticals sector.
With 1 pending office action, the administrative oversight for this portfolio is minimal. However, the reliance on the busiest examiner for 1 pending case means that the success of the current application depends on a single point of review. The focus on 1 distinct art unit highlights the specific nature of the technology being examined. Resolving the 1 pending case is the key current task for this portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOUNG, BRIAN ELLIS | 1 | 65.8% | +24.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18246959 | METHODS AND COMPOSITIONS FOR BIOLUMINESCENCE-BASED SEQUENCING | YOUNG, BRIAN ELLIS | 30d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18246959 | METHODS AND COMPOSITIONS FOR BIOLUMINESCENCE-BASED SEQUENCING | YOUNG, BRIAN ELLIS | 30d overdue |
| Art Unit | Apps |
|---|---|
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18246959 | METHODS AND COMPOSITIONS FOR BIOLUMINESCENCE-BASED SEQUENCING | YOUNG, BRIAN ELLIS | 1684 | §103§112 | Non-Final OA | 30d overdue | Pending | Mar 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial